Payment overview · 2025
General Payments
$3,829.37
171 reported records · 45 companies
Healthcare provider profile · identity verified
Dirk C Davidson, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CROSSVILLE, TN · NPI 1659369429
Verified facts
What the public records show
CMS Open Payments records show Dirk C Davidson, MD received $3,829.37 in general payments during 2025 across 171 reported records.
AstraZeneca Pharmaceuticals LP accounted for 7.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 89 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Calquence, Ibrance, Imbruvica, Inlyta, Keytruda, Lenvima, Libtayo, Orgovyx, Reblozyl, Tagrisso, Tecentriq, Venclexta, Verzenio, Xtandi.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IMBRUVICA as an associated drug or biological on 15599 records involving 6881 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Imbruvica by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUPRON DEPOT as an associated drug or biological on 6475 records involving 3205 distinct recipient NPIs. Public Medicare Part D data also shows 171 claims for Lupron Depot by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VENCLEXTA as an associated drug or biological on 10417 records involving 4944 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Venclexta by this doctor in 2024.
ARRAY BIOPHARMA INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IBRANCE as an associated drug or biological on 54 records involving 52 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Ibrance by this doctor in 2024.
ARRAY BIOPHARMA INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ORGOVYX as an associated drug or biological on 29 records involving 26 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Orgovyx by this doctor in 2024.
ARRAY BIOPHARMA INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XTANDI as an associated drug or biological on 98 records involving 88 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Xtandi by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Xtandi as an associated drug or biological on 11345 records involving 5418 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Xtandi by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CALQUENCE as an associated drug or biological on 8404 records involving 3935 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Calquence by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TAGRISSO as an associated drug or biological on 5285 records involving 2776 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Tagrisso by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 25 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Eliquis by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported POMALYST as an associated drug or biological on 282 records involving 237 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Pomalyst by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REBLOZYL as an associated drug or biological on 17361 records involving 5696 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Reblozyl by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Eliquis by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REBLOZYL as an associated drug or biological on 1732 records involving 943 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Reblozyl by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SPRYCEL as an associated drug or biological on 32 records involving 32 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Sprycel by this doctor in 2024.
Eisai Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Lenvima as an associated drug or biological on 16833 records involving 7014 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Lenvima by this doctor in 2024.
Genentech USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tecentriq as an associated drug or biological on 3585 records involving 2526 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Tecentriq by this doctor in 2024.
Genentech USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Venclexta as an associated drug or biological on 2896 records involving 2018 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Venclexta by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IMBRUVICA as an associated drug or biological on 47 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Imbruvica by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REMICADE as an associated drug or biological on 113 records involving 89 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Remicade by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CYRAMZA as an associated drug or biological on 19 records involving 6 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Cyramza by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERZENIO as an associated drug or biological on 9278 records involving 4763 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Verzenio by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported KEYTRUDA as an associated drug or biological on 46588 records involving 15767 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Keytruda by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LENVIMA as an associated drug or biological on 66 records involving 58 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Lenvima by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REBLOZYL as an associated drug or biological on 1175 records involving 979 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Reblozyl by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROMACTA as an associated drug or biological on 47 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Promacta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IBRANCE as an associated drug or biological on 11505 records involving 4934 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Ibrance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INLYTA as an associated drug or biological on 2646 records involving 1964 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Inlyta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ORGOVYX as an associated drug or biological on 16373 records involving 6981 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Orgovyx by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XTANDI as an associated drug or biological on 19368 records involving 7657 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Xtandi by this doctor in 2024.
Regeneron Healthcare Solutions, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LIBTAYO as an associated drug or biological on 22545 records involving 10925 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Libtayo by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTYVIO as an associated drug or biological on 61580 records involving 14953 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Entyvio by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GAMMAGARD LIQUID as an associated drug or biological on 29 records involving 8 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Gammagard Liquid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $302.04 | 7.9% | 11 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $299.16 | 7.8% | 15 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $227.82 | 6.0% | 9 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $227.07 | 5.9% | 11 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $188.64 | 4.9% | 7 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $187.15 | 4.9% | 9 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $167.10 | 4.4% | 10 | 2025 |
| Aveo Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $162.34 | 4.2% | 3 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $156.79 | 4.1% | 8 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $150.84 | 3.9% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $149.96 | 3.9% | 7 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $131.82 | 3.4% | 7 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $117.60 | 3.1% | 6 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $113.40 | 3.0% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $89.51 | 2.3% | 4 | 2025 |
| SEAGEN INC. | Unresolved — no canonical attribution shown | $77.99 | 2.0% | 1 | 2025 |
| Pharmacosmos Therapeutics Inc. | Unresolved — no canonical attribution shown | $75.24 | 2.0% | 4 | 2025 |
| Caris MPI, Inc. | Unresolved — no canonical attribution shown | $70.49 | 1.8% | 3 | 2025 |
| Exelixis Inc. | Unresolved — no canonical attribution shown | $67.07 | 1.8% | 3 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $64.75 | 1.7% | 2 | 2025 |
| Deciphera Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $59.32 | 1.6% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $58.98 | 1.5% | 3 | 2025 |
| BeOne Medicines USA, Inc. | Unresolved — no canonical attribution shown | $57.03 | 1.5% | 3 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $53.85 | 1.4% | 2 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $52.36 | 1.4% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $47.52 | 1.2% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $45.70 | 1.2% | 2 | 2025 |
| Sandoz Inc. | Unresolved — no canonical attribution shown | $37.18 | 1.0% | 2 | 2025 |
| TerSera Therapeutics LLC | Unresolved — no canonical attribution shown | $34.40 | 0.9% | 2 | 2025 |
| ARRAY BIOPHARMA INC | Unresolved — no canonical attribution shown | $32.75 | 0.9% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $30.06 | 0.8% | 2 | 2025 |
| PharmaEssentia USA Corporation | Unresolved — no canonical attribution shown | $27.29 | 0.7% | 1 | 2025 |
| AVYXA PHARMA, LLC | Unresolved — no canonical attribution shown | $26.83 | 0.7% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $22.82 | 0.6% | 1 | 2025 |
| pharmaand GmbH | Unresolved — no canonical attribution shown | $22.82 | 0.6% | 1 | 2025 |
| TAIHO ONCOLOGY, INC. | Unresolved — no canonical attribution shown | $22.02 | 0.6% | 1 | 2025 |
| AVEO Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.00 | 0.5% | 1 | 2025 |
| Acrotech Biopharma Inc. | Unresolved — no canonical attribution shown | $19.95 | 0.5% | 1 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.81 | 0.5% | 1 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $19.51 | 0.5% | 1 | 2025 |
| Spectrum Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.05 | 0.5% | 1 | 2025 |
| Rigel Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.87 | 0.5% | 1 | 2025 |
| Genmab U.S., Inc. | Unresolved — no canonical attribution shown | $18.78 | 0.5% | 1 | 2025 |
| BeiGene USA, Inc. | Unresolved — no canonical attribution shown | $18.13 | 0.5% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.56 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,613.33 | 167 |
| Education | $216.04 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KEYTRUDA Normalized: keytruda |
Biological | Merck Sharp & Dohme LLC | $196.37 | 8 | 2025 |
Source payment records
|
|||||
| Enhertu Normalized: enhertu |
Drug | Daiichi Sankyo Inc. | $188.64 | 7 | 2025 |
Source payment records
|
|||||
| FOTIVDA Normalized: fotivda |
Drug | AVEO Pharmaceuticals, Inc., Aveo Pharmaceuticals, Inc. | $182.34 | 4 | 2025 |
Source payment records
|
|||||
| REBLOZYL Normalized: reblozyl |
Biological | Celgene Corporation, Merck Sharp & Dohme LLC | $150.10 | 7 | 2025 |
Source payment records
|
|||||
| Trodelvy Normalized: trodelvy |
Drug | Gilead Sciences, Inc. | $117.60 | 6 | 2025 |
Source payment records
|
|||||
| TUKYSA Normalized: tukysa |
Drug | ARRAY BIOPHARMA INC, PFIZER INC. | $113.73 | 6 | 2025 |
Source payment records
|
|||||
| ELREXFIO Normalized: elrexfio |
Drug | PFIZER INC. | $101.88 | 5 | 2025 |
Source payment records
|
|||||
| IBRANCE Normalized: ibrance |
Drug | PFIZER INC. | $99.25 | 5 | 2025 |
Source payment records
|
|||||
| PADCEV Normalized: padcev |
Biological, Drug | Astellas Pharma US Inc, PFIZER INC. | $95.40 | 4 | 2025 |
Source payment records
|
|||||
| MONJUVI Normalized: monjuvi |
Drug | Incyte Corporation | $94.18 | 5 | 2025 |
Source payment records
|
|||||
| JAKAFI Normalized: jakafi |
Drug | Incyte Corporation | $92.97 | 4 | 2025 |
Source payment records
|
|||||
| JAYPIRCA Normalized: jaypirca |
Drug | Lilly USA, LLC | $89.51 | 4 | 2025 |
Source payment records
|
|||||
| VERZENIO Normalized: verzenio |
Drug | Lilly USA, LLC | $89.51 | 4 | 2025 |
Source payment records
|
|||||
| OPDIVO Normalized: opdivo |
Biological | E.R. Squibb & Sons, L.L.C. | $87.16 | 4 | 2025 |
Source payment records
|
|||||
| ADCETRIS Normalized: adcetris |
Biological | PFIZER INC. | $83.70 | 4 | 2025 |
Source payment records
|
|||||
| KISQALI Normalized: kisqali |
Drug | Novartis Pharmaceuticals Corporation | $83.59 | 4 | 2025 |
Source payment records
|
|||||
| IMBRUVICA Normalized: imbruvica |
Drug | ABBVIE INC. | $81.36 | 4 | 2025 |
Source payment records
|
|||||
| SCEMBLIX Normalized: scemblix |
Drug | Novartis Pharmaceuticals Corporation | $77.63 | 4 | 2025 |
Source payment records
|
|||||
| ORGOVYX Normalized: orgovyx |
Drug | PFIZER INC. | $75.53 | 4 | 2025 |
Source payment records
|
|||||
| TALZENNA Normalized: talzenna |
Drug | PFIZER INC. | $75.53 | 4 | 2025 |
Source payment records
|
|||||
| XTANDI Normalized: xtandi |
Drug | PFIZER INC. | $75.53 | 4 | 2025 |
Source payment records
|
|||||
| MONOFERRIC Normalized: monoferric |
Drug | Pharmacosmos Therapeutics Inc. | $75.24 | 4 | 2025 |
Source payment records
|
|||||
| MI CANCER SEEK Normalized: mi cancer seek |
Device | Caris MPI, Inc. | $70.49 | 3 | 2025 |
Source payment records
|
|||||
| CABOMETYX Normalized: cabometyx |
Drug | Exelixis Inc. | $67.07 | 3 | 2025 |
Source payment records
|
|||||
| RYBREVANT Normalized: rybrevant |
Drug | Janssen Biotech, Inc. | $66.90 | 5 | 2025 |
Source payment records
|
|||||
| AKEEGA Normalized: akeega |
Drug | Janssen Biotech, Inc. | $66.72 | 3 | 2025 |
Source payment records
|
|||||
| ERLEADA Normalized: erleada |
Drug | Janssen Biotech, Inc. | $66.72 | 3 | 2025 |
Source payment records
|
|||||
| LUTATHERA Normalized: lutathera |
Drug | Novartis Pharmaceuticals Corporation | $65.85 | 3 | 2025 |
Source payment records
|
|||||
| RETEVMO Normalized: retevmo |
Drug | Lilly USA, LLC | $64.91 | 3 | 2025 |
Source payment records
|
|||||
| LIBTAYO Normalized: libtayo |
Biological | Regeneron Healthcare Solutions, Inc. | $64.75 | 2 | 2025 |
Source payment records
|
|||||
| TECVAYLI Normalized: tecvayli |
Biological | Janssen Biotech, Inc. | $61.49 | 3 | 2025 |
Source payment records
|
|||||
| EPKINLY Normalized: epkinly |
Drug | ABBVIE INC., Genmab U.S., Inc. | $60.04 | 3 | 2025 |
Source payment records
|
|||||
| QINLOCK Normalized: qinlock |
Drug | Deciphera Pharmaceuticals Inc. | $59.32 | 2 | 2025 |
Source payment records
|
|||||
| ROMVIMZA Normalized: romvimza |
Drug | Deciphera Pharmaceuticals Inc. | $59.32 | 2 | 2025 |
Source payment records
|
|||||
| ZYNYZ Normalized: zynyz |
Drug | Incyte Corporation | $55.60 | 2 | 2025 |
Source payment records
|
|||||
| BRUKINSA Normalized: brukinsa |
Drug | BeOne Medicines USA, Inc., BeiGene USA, Inc. | $54.34 | 3 | 2025 |
Source payment records
|
|||||
| TAGRISSO Normalized: tagrisso |
Drug | AstraZeneca Pharmaceuticals LP | $54.19 | 2 | 2025 |
Source payment records
|
|||||
| Polivy Normalized: polivy |
Biological | Genentech USA, Inc. | $52.42 | 2 | 2025 |
Source payment records
|
|||||
| CALQUENCE Normalized: calquence |
Drug | AstraZeneca Pharmaceuticals LP | $51.92 | 2 | 2025 |
Source payment records
|
|||||
| IMFINZI Normalized: imfinzi |
Biological | AstraZeneca Pharmaceuticals LP | $49.59 | 2 | 2025 |
Source payment records
|
|||||
| VENCLEXTA Normalized: venclexta |
Drug | ABBVIE INC. | $48.66 | 2 | 2025 |
Source payment records
|
|||||
| Tecentriq Normalized: tecentriq |
Biological | Genentech USA, Inc. | $47.85 | 3 | 2025 |
Source payment records
|
|||||
| Lenvima Normalized: lenvima |
Drug | Eisai Inc. | $47.52 | 2 | 2025 |
Source payment records
|
|||||
| OPDUALAG Normalized: opdualag |
Drug | Celgene Corporation, E.R. Squibb & Sons, L.L.C. | $47.50 | 3 | 2025 |
Source payment records
|
|||||
| WELIREG Normalized: welireg |
Drug | Merck Sharp & Dohme LLC | $46.89 | 2 | 2025 |
Source payment records
|
|||||
| RUBRACA Normalized: rubraca |
Drug | TOLMAR, INC., pharmaand GmbH | $45.64 | 2 | 2025 |
Source payment records
|
|||||
| OJJAARA Normalized: ojjaara |
Drug | GlaxoSmithKline, LLC. | $40.51 | 2 | 2025 |
Source payment records
|
|||||
| Vyloy Normalized: vyloy |
Drug | Astellas Pharma US Inc | $40.50 | 2 | 2025 |
Source payment records
|
|||||
| BALVERSA Normalized: balversa |
Drug | Janssen Biotech, Inc. | $38.71 | 2 | 2025 |
Source payment records
|
|||||
| PEMAZYRE Normalized: pemazyre |
Drug | Incyte Corporation | $38.58 | 3 | 2025 |
Source payment records
|
|||||
| JUBBONTI Normalized: jubbonti |
Biological | Sandoz Inc. | $37.18 | 2 | 2025 |
Source payment records
|
|||||
| WYOST Normalized: wyost |
Biological | Sandoz Inc. | $37.18 | 2 | 2025 |
Source payment records
|
|||||
| Quzyttir Normalized: quzyttir |
Drug | TerSera Therapeutics LLC | $34.40 | 2 | 2025 |
Source payment records
|
|||||
| BRAFTOVI Normalized: braftovi |
Drug | ARRAY BIOPHARMA INC | $32.75 | 2 | 2025 |
Source payment records
|
|||||
| Itovebi Normalized: itovebi |
Biological | Genentech USA, Inc. | $31.55 | 2 | 2025 |
Source payment records
|
|||||
| FRUZAQLA Normalized: fruzaqla |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $30.49 | 1 | 2025 |
Source payment records
|
|||||
| Nubeqa Normalized: nubeqa |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $30.06 | 2 | 2025 |
Source payment records
|
|||||
| AYVAKIT Normalized: ayvakit |
Biological | GENZYME CORPORATION | $28.18 | 1 | 2025 |
Source payment records
|
|||||
| BESREMI Normalized: besremi |
Drug | PharmaEssentia USA Corporation | $27.29 | 1 | 2025 |
Source payment records
|
|||||
| AVGEMSI Normalized: avgemsi |
Drug | AVYXA PHARMA, LLC | $26.83 | 1 | 2025 |
Source payment records
|
|||||
| DOCIVYX Normalized: docivyx |
Drug | AVYXA PHARMA, LLC | $26.83 | 1 | 2025 |
Source payment records
|
|||||
| LUTRATE DEPOT Normalized: lutrate depot |
Drug | AVYXA PHARMA, LLC | $26.83 | 1 | 2025 |
Source payment records
|
|||||
| ICLUSIG Normalized: iclusig |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $23.36 | 1 | 2025 |
Source payment records
|
|||||
| ELIGARD Normalized: eligard |
Drug | TOLMAR, INC. | $22.82 | 1 | 2025 |
Source payment records
|
|||||
| KEYTRUDA QLEX Normalized: keytruda qlex |
Biological | Merck Sharp & Dohme LLC | $22.55 | 1 | 2025 |
Source payment records
|
|||||
| INLYTA Normalized: inlyta |
Drug | PFIZER INC. | $22.50 | 1 | 2025 |
Source payment records
|
|||||
| INQOVI Normalized: inqovi |
Drug | TAIHO ONCOLOGY, INC. | $22.02 | 1 | 2025 |
Source payment records
|
|||||
| LONSURF Normalized: lonsurf |
Drug | TAIHO ONCOLOGY, INC. | $22.02 | 1 | 2025 |
Source payment records
|
|||||
| GILOTRIF Normalized: gilotrif |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $21.55 | 1 | 2025 |
Source payment records
|
|||||
| TEVIMBRA Normalized: tevimbra |
Drug | BeOne Medicines USA, Inc. | $20.82 | 1 | 2025 |
Source payment records
|
|||||
| RYZNEUTA Normalized: ryzneuta |
Drug | Acrotech Biopharma Inc. | $19.95 | 1 | 2025 |
Source payment records
|
|||||
| ELAHERE Normalized: elahere |
Drug | ABBVIE INC. | $19.94 | 1 | 2025 |
Source payment records
|
|||||
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $19.81 | 1 | 2025 |
Source payment records
|
|||||
| BOSULIF Normalized: bosulif |
Drug | PFIZER INC. | $19.63 | 1 | 2025 |
Source payment records
|
|||||
| BREYANZI Normalized: breyanzi |
Biological | Celgene Corporation | $19.43 | 1 | 2025 |
Source payment records
|
|||||
| ROLVEDON Normalized: rolvedon |
Drug | Spectrum Pharmaceuticals Inc. | $19.05 | 1 | 2025 |
Source payment records
|
|||||
| Gavreto Normalized: gavreto |
Drug | Rigel Pharmaceuticals, Inc. | $18.87 | 1 | 2025 |
Source payment records
|
|||||
| Rezlidhia Normalized: rezlidhia |
Drug | Rigel Pharmaceuticals, Inc. | $18.87 | 1 | 2025 |
Source payment records
|
|||||
| TAVALISSE Normalized: tavalisse |
Drug | Rigel Pharmaceuticals, Inc. | $18.87 | 1 | 2025 |
Source payment records
|
|||||
| JEMPERLI Normalized: jemperli |
Biological | GlaxoSmithKline, LLC. | $18.47 | 1 | 2025 |
Source payment records
|
|||||
| ZEJULA Normalized: zejula |
Drug | GlaxoSmithKline, LLC. | $18.47 | 1 | 2025 |
Source payment records
|
|||||
| LORBRENA Normalized: lorbrena |
Drug | ARRAY BIOPHARMA INC | $18.27 | 1 | 2025 |
Source payment records
|
|||||
| DANZITEN Normalized: danziten |
Drug | Azurity Pharmaceuticals, Inc. | $17.56 | 1 | 2025 |
Source payment records
|
|||||
| VIVIMUSTA Normalized: vivimusta |
Drug | Azurity Pharmaceuticals, Inc. | $17.56 | 1 | 2025 |
Source payment records
|
|||||
| Stivarga Normalized: stivarga |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $15.55 | 1 | 2025 |
Source payment records
|
|||||
| Vitrakvi Normalized: vitrakvi |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $15.55 | 1 | 2025 |
Source payment records
|
|||||
| MEKTOVI Normalized: mektovi |
Drug | ARRAY BIOPHARMA INC | $14.48 | 1 | 2025 |
Source payment records
|
|||||
| Alecensa Normalized: alecensa |
Biological | Genentech USA, Inc. | $13.72 | 1 | 2025 |
Source payment records
|
|||||
| Tecentriq Hybreza Normalized: tecentriq hybreza |
Biological | Genentech USA, Inc. | $13.72 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CALQUENCE calquence |
2025 | Calquence | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| IBRANCE ibrance |
2025 | Ibrance | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| IMBRUVICA imbruvica |
2025 | Imbruvica | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INLYTA inlyta |
2025 | Inlyta | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| KEYTRUDA keytruda |
2025 | Keytruda | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Lenvima lenvima |
2025 | Lenvima | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LIBTAYO libtayo |
2025 | Libtayo | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ORGOVYX orgovyx |
2025 | Orgovyx | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REBLOZYL reblozyl |
2025 | Reblozyl | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TAGRISSO tagrisso |
2025 | Tagrisso | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Tecentriq tecentriq |
2025 | Tecentriq | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VENCLEXTA venclexta |
2025 | Venclexta | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VERZENIO verzenio |
2025 | Verzenio | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XTANDI xtandi |
2025 | Xtandi | 2024 | 133 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | IMBRUVICA open payments reported associated product |
CMS Open Payments — General Payments 15599 supporting records · 6881 recipient NPIs · example record 1201352838 |
Imbruvica · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUPRON DEPOT open payments reported associated product |
CMS Open Payments — General Payments 6475 supporting records · 3205 recipient NPIs · example record 1201352804 |
Lupron Depot · 2024 Exact normalized brand match · 1 Part D row |
171 | 64 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VENCLEXTA open payments reported associated product |
CMS Open Payments — General Payments 10417 supporting records · 4944 recipient NPIs · example record 1201353144 |
Venclexta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ARRAY BIOPHARMA INC Exact reporting entity; no affiliate inference |
2025 | IBRANCE open payments reported associated product |
CMS Open Payments — General Payments 54 supporting records · 52 recipient NPIs · example record 1228804288 |
Ibrance · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| ARRAY BIOPHARMA INC Exact reporting entity; no affiliate inference |
2025 | ORGOVYX open payments reported associated product |
CMS Open Payments — General Payments 29 supporting records · 26 recipient NPIs · example record 1228888885 |
Orgovyx · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ARRAY BIOPHARMA INC Exact reporting entity; no affiliate inference |
2025 | XTANDI open payments reported associated product |
CMS Open Payments — General Payments 98 supporting records · 88 recipient NPIs · example record 1228800820 |
Xtandi · 2024 Exact normalized brand match · 1 Part D row |
133 | 20 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Xtandi open payments reported associated product |
CMS Open Payments — General Payments 11345 supporting records · 5418 recipient NPIs · example record 1238560686 |
Xtandi · 2024 Exact normalized brand match · 1 Part D row |
133 | 20 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | CALQUENCE open payments reported associated product |
CMS Open Payments — General Payments 8404 supporting records · 3935 recipient NPIs · example record 1206131382 |
Calquence · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | TAGRISSO open payments reported associated product |
CMS Open Payments — General Payments 5285 supporting records · 2776 recipient NPIs · example record 1206131546 |
Tagrisso · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 25 supporting records · 24 recipient NPIs · example record 1184385048 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | POMALYST open payments reported associated product |
CMS Open Payments — General Payments 282 supporting records · 237 recipient NPIs · example record 1184378437 |
Pomalyst · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | REBLOZYL open payments reported associated product |
CMS Open Payments — General Payments 17361 supporting records · 5696 recipient NPIs · example record 1184377709 |
Reblozyl · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | REBLOZYL open payments reported associated product |
CMS Open Payments — General Payments 1732 supporting records · 943 recipient NPIs · example record 1184377805 |
Reblozyl · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | SPRYCEL open payments reported associated product |
CMS Open Payments — General Payments 32 supporting records · 32 recipient NPIs · example record 1184390211 |
Sprycel · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Eisai Inc. Exact reporting entity; no affiliate inference |
2025 | Lenvima open payments reported associated product |
CMS Open Payments — General Payments 16833 supporting records · 7014 recipient NPIs · example record 1244455619 |
Lenvima · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Genentech USA, Inc. Exact reporting entity; no affiliate inference |
2025 | Tecentriq open payments reported associated product |
CMS Open Payments — General Payments 3585 supporting records · 2526 recipient NPIs · example record 1211488420 |
Tecentriq · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Genentech USA, Inc. Exact reporting entity; no affiliate inference |
2025 | Venclexta open payments reported associated product |
CMS Open Payments — General Payments 2896 supporting records · 2018 recipient NPIs · example record 1211488584 |
Venclexta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | IMBRUVICA open payments reported associated product |
CMS Open Payments — General Payments 47 supporting records · 33 recipient NPIs · example record 1174328453 |
Imbruvica · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | REMICADE open payments reported associated product |
CMS Open Payments — General Payments 113 supporting records · 89 recipient NPIs · example record 1174377572 |
Remicade · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | CYRAMZA open payments reported associated product |
CMS Open Payments — General Payments 19 supporting records · 6 recipient NPIs · example record 1186466555 |
Cyramza · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | VERZENIO open payments reported associated product |
CMS Open Payments — General Payments 9278 supporting records · 4763 recipient NPIs · example record 1186464449 |
Verzenio · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | KEYTRUDA open payments reported associated product |
CMS Open Payments — General Payments 46588 supporting records · 15767 recipient NPIs · example record 1237992210 |
Keytruda · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | LENVIMA open payments reported associated product |
CMS Open Payments — General Payments 66 supporting records · 58 recipient NPIs · example record 1237995778 |
Lenvima · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | REBLOZYL open payments reported associated product |
CMS Open Payments — General Payments 1175 supporting records · 979 recipient NPIs · example record 1237992280 |
Reblozyl · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | PROMACTA open payments reported associated product |
CMS Open Payments — General Payments 47 supporting records · 47 recipient NPIs · example record 1200028032 |
Promacta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | IBRANCE open payments reported associated product |
CMS Open Payments — General Payments 11505 supporting records · 4934 recipient NPIs · example record 1228794164 |
Ibrance · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | INLYTA open payments reported associated product |
CMS Open Payments — General Payments 2646 supporting records · 1964 recipient NPIs · example record 1228795917 |
Inlyta · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ORGOVYX open payments reported associated product |
CMS Open Payments — General Payments 16373 supporting records · 6981 recipient NPIs · example record 1228794230 |
Orgovyx · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | XTANDI open payments reported associated product |
CMS Open Payments — General Payments 19368 supporting records · 7657 recipient NPIs · example record 1228794230 |
Xtandi · 2024 Exact normalized brand match · 1 Part D row |
133 | 20 |
| Regeneron Healthcare Solutions, Inc. Exact reporting entity; no affiliate inference |
2025 | LIBTAYO open payments reported associated product |
CMS Open Payments — General Payments 22545 supporting records · 10925 recipient NPIs · example record 1212855234 |
Libtayo · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | ENTYVIO open payments reported associated product |
CMS Open Payments — General Payments 61580 supporting records · 14953 recipient NPIs · example record 1223616258 |
Entyvio · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | GAMMAGARD LIQUID open payments reported associated product |
CMS Open Payments — General Payments 29 supporting records · 8 recipient NPIs · example record 1223786557 |
Gammagard Liquid · 2024 Exact normalized brand match · 1 Part D row |
77 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Letrozole | Letrozole | 391 | 104 |
| Lupron Depot | Leuprolide Acetate | 171 | 64 |
| Prolia | Denosumab | 165 | 105 |
| Hydroxyurea | Hydroxyurea | 164 | 32 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 145 | 44 |
| Anastrozole | Anastrozole | 136 | 38 |
| Xtandi | Enzalutamide | 133 | 20 |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 130 | 84 |
| Oxycodone Hcl | Oxycodone Hcl | 105 | 20 |
| Prednisone | Prednisone | 97 | 50 |
| Tamoxifen Citrate | Tamoxifen Citrate | 94 | 21 |
| Levothyroxine Sodium | Levothyroxine Sodium | 80 | 18 |
| Gammagard Liquid | Immun Glob G(Igg)/Gly/Iga Ov50 | 77 | 11 |
| Neulasta Onpro | Pegfilgrastim | 75 | 18 |
| Palonosetron Hcl | Palonosetron Hcl | 75 | 21 |
| Zoledronic Acid | Zoledronic Acid/Mannitol-Water | 75 | 75 |
| Granisetron Hcl | Granisetron Hcl/Pf | 74 | 23 |
| Xgeva | Denosumab | 73 | 17 |
| Fulvestrant | Fulvestrant | 69 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 67 | 36 |
| Alprazolam | Alprazolam | 61 | 12 |
| Dexamethasone | Dexamethasone | 60 | 29 |
| Procrit | Epoetin Alfa | 57 | 22 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 50 | 18 |
| Sandostatin Lar Depot | Octreotide Acetate,mi-Spheres | 50 | suppressed |
| Lenalidomide | Lenalidomide | 45 | suppressed |
| Potassium Chloride | Potassium Chloride | 45 | 17 |
| Zoledronic Acid | Zoledronic Acid | 41 | 16 |
| Omeprazole | Omeprazole | 40 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 39 | 15 |
| Tramadol Hcl | Tramadol Hcl | 39 | 13 |
| Darzalex Faspro | Daratumumab-Hyaluronidase-Fihj | 38 | suppressed |
| Imbruvica | Ibrutinib | 38 | suppressed |
| Acyclovir | Acyclovir | 37 | 11 |
| Morphine Sulfate Er | Morphine Sulfate | 37 | 11 |
| Tecentriq | Atezolizumab | 36 | suppressed |
| Ondansetron Odt | Ondansetron | 35 | 24 |
| Ibrance | Palbociclib | 33 | suppressed |
| Keytruda | Pembrolizumab | 33 | suppressed |
| Carboplatin | Carboplatin | 32 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 32 | 21 |
| Revlimid | Lenalidomide | 32 | suppressed |
| Gemcitabine Hcl | Gemcitabine Hcl | 29 | suppressed |
| Imatinib Mesylate | Imatinib Mesylate | 29 | suppressed |
| Zirabev | Bevacizumab-Bvzr | 27 | suppressed |
| Calquence | Acalabrutinib Maleate | 25 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 25 | suppressed |
| Docetaxel | Docetaxel | 24 | suppressed |
| Fosaprepitant Dimeglumine | Fosaprepitant Dimeglumine | 24 | suppressed |
| Inlyta | Axitinib | 24 | suppressed |
| Libtayo | Cemiplimab-Rwlc | 24 | suppressed |
| Tagrisso | Osimertinib Mesylate | 23 | suppressed |
| Movantik | Naloxegol Oxalate | 22 | suppressed |
| Reblozyl | Luspatercept-Aamt | 22 | suppressed |
| Bortezomib | Bortezomib | 21 | suppressed |
| Cyclophosphamide | Cyclophosphamide | 21 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 20 | suppressed |
| Tysabri | Natalizumab | 20 | suppressed |
| Eliquis | Apixaban | 18 | suppressed |
| Sprycel | Dasatinib | 18 | suppressed |
| Lenvima | Lenvatinib Mesylate | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Orgovyx | Relugolix | 16 | suppressed |
| Truxima | Rituximab-Abbs | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 15 |
| Exemestane | Exemestane | 15 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Pomalyst | Pomalidomide | 15 | suppressed |
| Ruxience | Rituximab-Pvvr | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Entyvio | Vedolizumab | 14 | suppressed |
| Fentanyl | Fentanyl | 14 | suppressed |
| Promacta | Eltrombopag Olamine | 14 | suppressed |
| Verzenio | Abemaciclib | 14 | suppressed |
| Retacrit | Epoetin Alfa-Epbx | 13 | suppressed |
| Leucovorin Calcium | Leucovorin Calcium | 12 | suppressed |
| Venclexta | Venetoclax | 12 | suppressed |
| Cyramza | Ramucirumab | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Mekinist | Trametinib Dimethyl Sulfoxide | 11 | suppressed |
| Remicade | Infliximab | 11 | suppressed |
| Tafinlar | Dabrafenib Mesylate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,829.37 · 171 records | AstraZeneca Pharmaceuticals LP | ADCETRIS, AKEEGA, AVGEMSI, AYVAKIT, Alecensa, BALVERSA, BESREMI, BOSULIF, BRAFTOVI, BREYANZI, BRUKINSA, CABOMETYX, CALQUENCE, DANZITEN, DOCIVYX, ELAHERE, ELIGARD, ELREXFIO, EPKINLY, ERLEADA, Enhertu, FOTIVDA, FRUZAQLA, GILOTRIF, Gavreto, IBRANCE, ICLUSIG, IMBRUVICA, IMFINZI, INLYTA, INQOVI, Itovebi, JAKAFI, JAYPIRCA, JEMPERLI, JUBBONTI, KEYTRUDA, KEYTRUDA QLEX, KISQALI, LIBTAYO, LONSURF, LORBRENA, LUTATHERA, LUTRATE DEPOT, Lenvima, MEKTOVI, MI CANCER SEEK, MONJUVI, MONOFERRIC, Nubeqa, OJJAARA, OPDIVO, OPDUALAG, ORGOVYX, PADCEV, PEMAZYRE, PYRUKYND, Polivy, QINLOCK, Quzyttir, REBLOZYL, RETEVMO, ROLVEDON, ROMVIMZA, RUBRACA, RYBREVANT, RYZNEUTA, Rezlidhia, SCEMBLIX, Stivarga, TAGRISSO, TALZENNA, TAVALISSE, TECVAYLI, TEVIMBRA, TUKYSA, Tecentriq, Tecentriq Hybreza, Trodelvy, VENCLEXTA, VERZENIO, VIVIMUSTA, Vitrakvi, Vyloy, WELIREG, WYOST, XTANDI, ZEJULA, ZYNYZ | 35 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Calquence play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error